secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036288
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech to present updated Versamune HPV Phase 2 data at ASTRO 2024
-----------------------------------------------------------------------

- Updated IMMUNOCERV Phase 2 data for Versamune® HPV (PDS0101) with chemoradiation in locally advanced cervical cancer accepted for oral presentation at ASTRO 2024.
- Presentation scheduled for Oct 1, 2024, 2:50-3:00 p.m. ET; lead author Dr. Adam Grippin from MD Anderson.
- No specific efficacy results disclosed in this press release; investors await presentation for updated data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124036288/0001140361-24-036288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124036288/ef20033761_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer